Ginkgo Bioworks Holdings (DNA) Operating Leases (2022 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Operating Leases came in at $410.7 million in Q1 2026, down 5.49% YoY from $434.6 million in Q1 2025, and down 1.53% on a QoQ basis from $417.1 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Operating Leases (2022 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 5 years of Operating Leases data on file, last reported at $410.7 million in Q1 2026.
- Quarterly Operating Leases fell 5.49% year-over-year to $410.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $410.7 million (down 5.49% YoY) and the FY2025 annual result came in at $417.1 million, down 4.94% from the prior year.
- Operating Leases fell to $410.7 million in Q1 2026, from $417.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $452.3 million in Q2 2024 to a low of $221.8 million in Q4 2023.
- A 5-year average of $395.6 million and a median of $415.2 million in 2022 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2023 — Operating Leases tumbled 46.32% — and 2024, when it jumped 97.79%.
- Tracing DNA's Operating Leases over 5 years: stood at $413.3 million in 2022, then tumbled by 46.32% to $221.8 million in 2023, then soared by 97.79% to $438.8 million in 2024, then declined by 4.94% to $417.1 million in 2025, then declined by 1.53% to $410.7 million in 2026.
- The last three Operating Leases figures came in at $410.7 million (Q1 2026), $417.1 million (Q4 2025), and $422.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 404.11 Mn |
| Mar 31, 2026 | 410.70 Mn |
| Dec 31, 2025 | 417.08 Mn |
| Sep 30, 2025 | 422.87 Mn |
| Jun 30, 2025 | 428.83 Mn |
| Mar 31, 2025 | 434.56 Mn |
| Dec 31, 2024 | 438.77 Mn |
| Sep 30, 2024 | 445.59 Mn |
| Jun 30, 2024 | 452.27 Mn |
| Mar 31, 2024 | 234.50 Mn |
| Dec 31, 2023 | 221.84 Mn |
| Sep 30, 2023 | 403.66 Mn |
| Jun 30, 2023 | 410.94 Mn |
| Mar 31, 2023 | 404.10 Mn |
| Dec 31, 2022 | 413.26 Mn |